The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis

Abstract

Purpose: Genetic mutations may play an important role in the progression and invasion of thyroid carcinoma (TC), and their coexistence may result in mutational synergy. The presence of the BRAF V600E mutation, as well as mutations affecting the TERT promoter, RAS, CHEK2 and RET/PTC, may all have an impact on prognosis. The aim of this study was to explore whether synergy between the coexistent mutations predicts histopathological prognostic factors that influence disease outcome. Methods: A comprehensive literature search of PubMed, Embase and the Cochrane Library, from their inception until January 2020. Primary outcomes included: disease stage, lymph node metastasis, extrathyroidal extension and distant metastasis; while, secondary outcomes included: tumor recurrence, mortality, invasion of thyroid capsule, multiplicity, presented as an odds ratio (OR) with 95% credible intervals (CrI). Results: 27 publications (comprising 9 active intervention arms), involving 8,388 TC patients, were selected. Network meta-analytic estimates of active interventions contrasted with other active interventions, with random effects, were calculated. In terms of outcomes focus on overall TC, BRAF V600E + TERT co-mutation ranked highest for diseases stage (OR = 5.74, 95% CrI: 3.09-10.66), as well as lymph node metastasis, extrathyroidal extension (5.74, 4.06-8.10), tumor recurrence (7.21, 3.59-14.47), and invasion of the thyroid capsule (3.11, 1.95-4.95). BRAF V600E + TERT co-mutation ranked secondary in distant metastasis, mortality, and multiplicity that ranked highest was TERT+ RAS or RAS. When we were limited to the study of patients with papillary TC (PTC), BRAF V600E + TERT always ranked highest for primary outcomes: disease stage (6.39, 3.13-13.04), lymph node metastasis, extrathyroidal extension (5.80,3.89-8.64) and

CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways

“…The major mode of programmed cell death is apoptosis, a highly regulated ordered cell destruction meant to remove damaged or redundant cells. Controlling apoptosis is an important focus of cancer treatment ( 62 – 64 ). Apoptosis can occur through two signaling pathways: an “external” pathway mediated by death receptors and an “internal” pathway mediated by mitochondria.…”

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling

“…A breakthrough in understanding the pathogenesis of LCH occurred in 2010 when a gain-of-function mutation in B-RAF (V600E) was identified in more than half of LCH patient samples [21]. Similar to in melanoma [22], colon [23], and thyroid cancer [24], BRAF V600E marks poor outcomes. In a series of 315 children with LCH, the B-RAF V600E mutation was correlated with aggressive disease and resistance to chemotherapy [25].…”

Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers

“…A combination of BRAF V600E and TERT has been noticed in all thyroid cancer histotypes, but it has specific significance in PTC. A significant correlation was found with patients age, ETE, LNM, distant metastasis, disease stage, tumor recurrence, mortality, and thyroid capsule invasion [ 35 , 36 ].…”